The importance of Raf dimerization in cell signaling

Small GTPases

Volumn 4, Issue 3, 2013, Pages

  Freeman, Alyson K ^a   Ritt, Daniel A ^a   Morrison, Deborah K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B Raf; C Raf; ERK cascade; MEK; Raf family kinases; Ras

Indexed keywords

RAF PROTEIN; RAS PROTEIN; VEMURAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; BINDING SITE; CANCER CELL CULTURE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; DIMERIZATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; NOTE; PHARMACOLOGICAL BLOCKING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NEOPLASMS;

DIMERIZATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84887553103     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.26117     Document Type: Note

References (26)

1. Hagemann C, Rapp UR. Isotype-specific functions of Raf kinases. Exp Cell Res 1999; 253:34-46; PMID:10579909; http://dx.doi.org/10.1006/excr.1999.4689
2. Wellbrock C, Karasarides M, Marais R. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004; 5:875-885; PMID:15520807; http://dx.doi.org/10.1038/nrm1498
3. Dougherty MK, Müller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17:215-224; P M I D: 15 6 6 4 191; http://dx.doi.org/10.1016/j. molcel.2004.11.055
4. Ritt DA, Monson DM, Specht SI, Morrison DK. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol 2010; 30:806-819; PMID:19933846; http://dx.doi.org/10.1128/MCB.00569-09
5. Luo Z, Tzivion G, Belshaw PJ, Vavvas D, Marshall M, Avruch J. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 1996; 383:181-185; PMID:8774885; http://dx.doi.org/10.1038/383181a0
6. Farrar MA, Alberol-Ila J, Perlmutter RM. Activation of the Raf-1 kinase cascade by cou-mermycin-induced dimerization. Nature 1996; 383:178-181; PMID:8774884; http://dx.doi. org/10.1038/383178a0
7. Weber CK, Slupsky JR, Kalmes HA, Rapp UR. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 2001; 61:3595-3598; PMID:11325826
8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, et al.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6
9. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dys-regulation. Curr Opin Genet Dev 2009; 19:230-236; PM I D:19 4 67855; http://dx.doi.org/10.1016/j. gde.2009.04.001
10. Röring M, Brummer T. Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. Crit Rev Oncog 2012; 17:97-121; PMID:22471666; http://dx.doi.org/10.1615/CritRevOncog.v17.i1.70
11. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963-969; PMID:16364920; http://dx.doi.org/10.1016/j.molcel.2005.10.022
12. Rushworth LK, Hindley AD, O'Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 2006; 26:2262-2272; PMID:16508002; http://dx.doi.org/10.1128/ MCB.26.6.2262-2272.2006
13. Rajakulendran T, Sahmi M, Lefrançois M, Sicheri F, Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009; 461:542-545; PMID:19727074; http://dx.doi. org/10.1038/nature08314
14. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431-435; PMID:20130576; http://dx.doi.org/10.1038/nature08833
15. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209-221; PM I D: 2 0141835; http://dx.doi.org/10.1016/j.cell.2009.12.040
16. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427-430; PMID:20179705; http://dx.doi.org/10.1038/nature08902
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954; PMID:12068308; http://dx.doi.org/10.1038/ nature00766
18. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207-215; PMID:22256804; http://dx.doi.org/10.1056/NEJMoa1105358
19. Freeman AK, Ritt DA, Morrison DK. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell 2013; 49:751-758; PMID:23352452; http://dx.doi.org/10.1016/j. molcel.2012.12.018
20. Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S, Capper D, von Deimling A, Schamel W W, et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J 2012; 31:2629-647; PMID:22510884; http://dx.doi. org/10.1038/emboj.2012.100
21. Wu X, Yin J, Simpson J, Kim KH, Gu S, Hong JH, Bayliss P, Backx PH, Neel BG, Araki T. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol 2012; 32:3872-3890; PMID:22826437; http://dx.doi.org/10.1128/ MCB.00751-12
22. Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/ MEK/ERK pathway. Genes Dev 2012; 26:1945-1958; PMID:22892241; http://dx.doi.org/10.1101/gad.193458.112
23. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013; 110:5957-5962; PMID:23533272; http://dx.doi.org/10.1073/pnas.1219232110
24. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atef M, Titz B, Gabay MT, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480:387-390; PM ID:22113612; http://dx.doi.org/10.1038/nature10662
25. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med 2011; 364:772-774; PMID:21345109; http://dx.doi.org/10.1056/ NEJMcibr1013704
26. Lavoie H, Thevakumaran N, Gavory G, Li JJ, Padeganeh A, Guiral S, Duchaine J, Mao DY, Bouvier M, Sicheri F, et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol 2013; 9:428-436; PMID:23685672; http://dx.doi.org/10.1038/nchembio.1257